CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Barostim's Promise | Explore CVRx's innovative heart failure treatment, targeting a $3.7B market with strong revenue growth and impressive gross profit margins |
Reimbursement Hurdles | Learn about CVRx's critical reimbursement challenges, including the transition to Category I CPT codes and potential impacts on procedure pricing |
Adoption Challenges | Delve into the obstacles CVRx faces in increasing physician awareness and generating real-world evidence for broader Barostim adoption |
Financial Outlook | Analyst targets range from $13 to $22, with CVRx's growth potential justifying premium valuation multiples despite current unprofitability |
Metrics to compare | CVRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCVRXPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.4x | −6.5x | −0.5x | |
PEG Ratio | −0.27 | −0.12 | 0.00 | |
Price/Book | 2.5x | 5.5x | 2.6x | |
Price / LTM Sales | 3.3x | 3.3x | 3.1x | |
Upside (Analyst Target) | 70.4% | 46.2% | 47.8% | |
Fair Value Upside | Unlock | −1.4% | 6.9% | Unlock |